Q-omics provides the consensus-scored CRYBB1 profile across patient tissues and cancer cell-line models. CRYBB1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CRYBB1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CRYBB1 RNA expression shows 17,031 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where CRYBB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYBB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYBB1 survival associations across molecular data types. CRYBB1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYBB1 RNA expression–survival associations across cancer types. High CRYBB1 expression shows unfavorable associations in LUSC, STAD and LAML, but favorable associations in UCEC, SKCM and CHOL. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for CRYBB1 RNA expression.
This table summarizes CRYBB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CRYBB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYBB1 shows lower tumor expression in BLCA, LUSC and PAAD and higher tumor expression in KIRC, KIRP and HNSC. The KIRC box plot shows higher CRYBB1 RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with CRYBB1 in patient tissues and cancer cell lines. In patient samples, CRYBB1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYBB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
